Skip to main content

NovoCure Ltd 8-K, filed Nov 9, 2026

NovoCure Ltd (NVCR)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

NovoCure Ltd filed this 8-K on November 9, 2026.

NovoCure Limited announced on November 9, 2026 that the FDA issued a Not Approvable Letter for Optune Mya, citing uncertainty about clinical benefit but no safety concerns. It plans to discuss approval options that would not require additional clinical studies. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits